Oral presentation
Adult bronchiectasis: risk factors and future perspectives
10:45
Idiopathic and post-infective bronchiectasis show no clinically important differences in outcomes or airway inflammatory profiles
J. Hill(Dundee (Angus), United Kingdom)
COI
1
11:00
Impact of co-morbidities on disease severity and risk of mortality in non-cystic fibrosis bronchiectasis
M. McDonnell(Oranmore (Co Galway), Ireland)
COI
2
11:15
Determinants and assessment of excess cardiovascular risk in bronchiectasis
A. Saleh(London, United Kingdom)
COI
3
11:30
Thrombocytosis is associated with disease severity and outcomes in stable bronchiectasis
D. Renton(Dundee (Angus), United Kingdom)
COI
4
11:45
Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort
P. Mitchelmore(Kenton, United Kingdom)
COI
5
12:00
A comprehensive analysis of the impact of pseudomonas aeruginosa colonisation in adult bronchiectasis
S. Finch(Perth, United Kingdom)
COI
6
12:15
Non-CF bronchiectasis impact on hospital admissions – Need to change the paradigm
J. Cordeiro Da Costa(Lousada, Portugal)
COI
7
12:30
Research priorities in bronchiectasis: A consensus from the European multicentre bronchiectasis audit and research collaboration (EMBARC) study group
S. Aliberti(Milano (MI), Italy)
COI
8
. . .
